Michael Thurn

Dr Michael Thurn has over two decades of experience in the life sciences and biotechnology industry, and has accumulated extensive knowledge in drug regulation, drug discovery, pre-clinical and clinical development across dermatology in Australia and the US. He has held various senior executive, managerial and board positions in listed and private companies. Dr Thurn has worked with the Therapeutic Goods Administration in Australia, led the clinical development of a topical acne treatment through to completion of Phase 2 clinical trial, and also led Spinifex Pharmaceuticals which was sold to Novartis in a $700m transaction.
Bio last updated 23 Feb 2019

Article Timeline

Network Graph

Displaying all related organisations and their related contacts. Hover over a node to display a link to the BNiQ page for that person or organisation.

Access to our data for Michael Thurn is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Michael Thurn is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 30/04/20

1 year TSR5 year TSR
289thResApp Health3%82%
687thBotanix Pharmaceuticals-54%12%
674 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®


Chief Operating Officer, Head of Australian Operations, Executive Director since 2019
Year started and most recent title

Share Transactions

$0 Other
$0 Issued
Total value as at the date of the transaction
Powered by Morningstar ®


93rd↑Botanix Pharmaceuticals$4.7m
104th↑ResApp Health$2.7m
109th↑Affinity Energy and Health$2.6m
197 listed industrial companies ranked by revenue.
Powered by Morningstar ®